Lentivirus-Mediated Expression of Human Secreted Amyloid Precursor Protein-Alpha Promotes Long-Term Induction of Neuroprotective Genes and Pathways in a Mouse Model of Alzheimer’s Disease
Restricted accessResearch articleFirst published online February 2, 2021
Lentivirus-Mediated Expression of Human Secreted Amyloid Precursor Protein-Alpha Promotes Long-Term Induction of Neuroprotective Genes and Pathways in a Mouse Model of Alzheimer’s Disease
Secreted amyloid precursor protein-alpha (sAPPα) can enhance memory and is neurotrophic and neuroprotective across a range of disease-associated insults, including amyloid-β toxicity. In a significant step toward validating sAPPα as a therapeutic for Alzheimer’s disease (AD), we demonstrated that long-term overexpression of human sAPPα (for 8 months) in a mouse model of amyloidosis (APP/PS1) could prevent the behavioral and electrophysiological deficits that develop in these mice.
Objective:
To explore the underlying molecular mechanisms responsible for the significant physiological and behavioral improvements observed in sAPPα-treated APP/PS1 mice.
Methods:
We assessed the long-term effects on the hippocampal transcriptome following continuous lentiviral delivery of sAPPα or empty-vector to male APP/PS1 mice and wild-type controls using Affymetrix Mouse Transcriptome Assays. Data analysis was carried out within the Affymetrix Transcriptome Analysis Console and an integrated analysis of the resulting transcriptomic data was performed with Ingenuity Pathway analysis (IPA).
Results:
Mouse transcriptome assays revealed expected AD-associated gene expression changes in empty-vector APP/PS1 mice, providing validation of the assays used for the analysis. By contrast, there were specific sAPPα-associated gene expression profiles which included increases in key neuroprotective genes such as Decorin, betaine-GABA transporter and protocadherin beta-5, subsequently validated by qRT-PCR. An integrated biological pathways analysis highlighted regulation of GABA receptor signaling, cell survival and inflammatory responses. Furthermore, upstream gene regulatory analysis implicated sAPPα activation of Interleukin-4, which can counteract inflammatory changes in AD.
Conclusion:
This study identified key molecular processes that likely underpin the long-term neuroprotective and therapeutic effects of increasing sAPPα levels in vivo
Sogorb-EsteveA, Garcia-AyllonMS, GobomJ, AlomJ, ZetterbergH, BlennowK, Saez-ValeroJ (2018) Levels of ADAM10 are reduced in Alzheimer’s disease CSF. J Neuroinflammation15, 213.
2.
ColciaghiF, BorroniB, PastorinoL, MarcelloE, ZimmermannM, CattabeniF, PadovaniA, Di LucaM (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med8, 67–74.
3.
MockettBG, RichterM, AbrahamWC, MullerUC (2017) Therapeutic potential of secreted amyloid precursor protein APPsalpha. Front Mol Neurosci10, 30.
4.
HabibA, SawmillerD, TanJ (2017) Restoring soluble amyloid precursor protein alpha functions as a potential treatment for Alzheimer’s disease. J Neurosci Res95, 973–991.
5.
MüllerUC, DellerT, KorteM (2017) Not just amyloid: Physiological functions of the amyloid precursor protein family. Nat Rev Neurosci18, 281.
6.
SiopiE, Llufriu-DabenG, ChoAH, Vidal-LletjosS, PlotkineM, Marchand-LerouxC, Jafarian-TehraniM (2013) Etazolate, an alpha-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology67, 183–192.
7.
CorriganF, VinkR, BlumbergsPC, MastersCL, CappaiR, van den HeuvelC (2012) sAPPalpha rescues deficits in APP knockout mice following focal traumatic brain injury. J Neurochem122, 208–220.
8.
SennvikK, FastbomJ, BlombergM, WahlundLO, WinbladB, BenedikzE (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett278, 169–172.
9.
LannfeltL, BasunH, WahlundLO, RoweBA, WagnerSL (1995) Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nat Med1, 829–832.
10.
AndersonJJ, HoltzG, BaskinPP, WangR, MazzarelliL, WagnerSL, MenzaghiF (1999) Reduced cerebrospinal fluid levels of alpha-secretase-cleaved amyloid precursor protein in aged rats: Correlation with spatial memory deficits. Neuroscience93, 1409–1420.
11.
EndresK, DellerT (2017) Regulation of alpha-secretase ADAM10 in vitro and in vivo : Genetic, epigenetic, and protein-based mechanisms. Front Mol Neurosci10, 56.
12.
TanVTY, MockettBG, OhlineSM, ParfittKD, WickyHE, PeppercornK, SchoderboeckL, YahayaMFB, TateWP, HughesSM, AbrahamWC (2018) Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer’s disease. Mol Brain11, 7.
13.
FolR, BraudeauJ, LudewigS, AbelT, WeyerSW, RoedererJP, BrodF, AudrainM, BemelmansAP, BuchholzCJ, KorteM, CartierN, MullerUC (2016) Viral gene transfer of APPsalpha rescues synaptic failure in an Alzheimer’s disease mouse model. Acta Neuropathol131, 247–266.
14.
JankowskyJL, SluntHH, RatovitskiT, JenkinsNA, CopelandNG, BorcheltDR (2001) Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng17, 157–165.
15.
AhmadF, SinghK, DasD, GowaikarR, ShawE, RamachandranA, RupanagudiKV, KommaddiRP, BennettDA, RavindranathV (2017) Reactive oxygen species-mediated loss of synaptic Akt1 signaling leads to deficient activity-dependent protein translation early in Alzheimer’s disease. Antioxid Redox Signal27, 1269–1280.
16.
JankowskyJL, FadaleDJ, AndersonJ, XuGM, GonzalesV, JenkinsNA, CopelandNG, LeeMK, YounkinLH, WagnerSL, YounkinSG, BorcheltDR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet13, 159–170.
17.
LeeJE, HanPL (2013) An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp Neurobiol22, 84–95.
18.
SavonenkoA, XuGM, MelnikovaT, MortonJL, GonzalesV, WongMP, PriceDL, TangF, MarkowskaAL, BorcheltDR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis18, 602–617.
19.
RyanMM, MorrisGP, MockettBG, BourneK, AbrahamWC, TateWP, WilliamsJM (2013) Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus. BMC Genomics14, 376.
20.
RyanMM, GuevremontD, MockettBG, AbrahamWC, WilliamsJM (2018) Circulating plasma microRNAs are altered with amyloidosis in a mouse model of Alzheimer’s disease. J Alzheimers Dis66, 835–852.
21.
SchroederA, MuellerO, StockerS, SalowskyR, LeiberM, GassmannM, LightfootS, MenzelW, GranzowM, RaggT (2006) The RIN: An RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol7, 3.
22.
EfronB, TibshiraniR (2002) Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol23, 70–86.
Lopez-GonzalezI, SchluterA, AsoE, Garcia-EsparciaP, AnsoleagaB, FLL, CarmonaM, MorenoJ, FusoA, Portero-OtinM, PamplonaR, PujolA, FerrerI (2015) Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: Correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol74, 319–344.
25.
PernotF, DorandeuF, BeaupC, PeinnequinA (2010) Selection of reference genes for real-time quantitative reverse transcription-polymerase chain reaction in hippocampal structure in a murine model of temporal lobe epilepsy with focal seizures. J Neurosci Res88, 1000–1008.
26.
KangY, WuZ, Cai LuB (2018) Evaluation of reference genes for gene expression studies in mouse and N2a cell ischemic stroke models using quantitative real-time PCR. BMC Neurosci19, 3.
27.
AithalMG, RajeswariN (2015) Validation of housekeeping genes for gene expression analysis in glioblastoma using quantitative real-time polymerase chain reaction. Brain Tumor Res Treat3, 24–29.
28.
PfafflMW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res29, e45.
29.
SchmittgenTD, LivakKJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc3, 1101–1108.
30.
AbidNB, NaseerMI, KimMO (2019) Comparative gene-expression analysis of Alzheimer’s disease progression with aging in transgenic mouse model. Int J Mol Sci20, 1219.
31.
DickeyCA, GordonMN, MasonJE, WilsonNJ, DiamondDM, GuzowskiJF, MorganD (2004) Amyloid suppresses induction of genes critical for memory consolidation in APP+PS1 transgenic mice. J Neurochem88, 434–442.
HendrickxA, PierrotN, TasiauxB, SchakmanO, Kienlen-CampardP, De SmetC, OctaveJN (2014) Epigenetic regulations of immediate early genes expression involved in memory formation by the amyloid precursor protein of Alzheimer disease. PLoS One9, e99467.
35.
ColesCA, MaksimovicJ, WadesonJ, FahriFT, WebsterT, LeytonC, McDonaghMB, WhiteJD (2018) Knockdown of a disintegrin A metalloprotease 12 (ADAM12) during adipogenesis reduces cell numbers, delays differentiation, and increases lipid accumulation in 3T3-L1 cells. Mol Biol Cell29, 1839–1855.
36.
KveiborgM, AlbrechtsenR, CouchmanJR, WewerUM (2008) Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol40, 1685–1702.
37.
SchonrockN, KeYD, HumphreysD, StaufenbielM, IttnerLM, PreissT, GotzJ (2010) Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. PLoS One5, e11070.
38.
VarendiK, KumarA, HarmaMA, AndressooJO (2014) miR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF. Cell Mol Life Sci71, 4443–4456.
LauP, BossersK, JankyR, SaltaE, FrigerioCS, BarbashS, RothmanR, SierksmaAS, ThathiahA, GreenbergD, PapadopoulouAS, AchselT, AyoubiT, SoreqH, VerhaagenJ, SwaabDF, AertsS, De StrooperB (2013) Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med5, 1613–1634.
41.
MorrisonJH, HofPR (2002) Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer’s disease. Prog Brain Res136, 467–486.
42.
WalshDM, SelkoeDJ (2004) Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron44, 181–193.
43.
MacGibbonGA, LawlorPA, WaltonM, SirimanneE, FaullRL, SynekB, MeeE, ConnorB, DragunowM (1997) Expression of Fos, Jun, and Krox family proteins in Alzheimer’s disease. Exp Neurol147, 316–332.
44.
HondiusDC, van NieropP, LiKW, HoozemansJJ, van der SchorsRC, van HaastertES, van der ViesSM, RozemullerAJ, SmitAB (2016) Profiling the human hippocampal proteome at all pathologic stages of Alzheimer’s disease. Alzheimers Dement12, 654–668.
45.
SauraCA, Parra-DamasA, Enriquez-BarretoL (2015) Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease. Front Cell Neurosci9, 318.
LiangWS, DunckleyT, BeachTG, GroverA, MastroeniD, RamseyK, CaselliRJ, KukullWA, McKeelD, MorrisJC, HuletteCM, SchmechelD, ReimanEM, RogersJ, StephanDA (2008) Altered neuronal gene expression in brain regions differentially affected by Alzheimer’s disease: A reference data set. Physiol Genomics33, 240–256.
48.
KongW, MouX, ZhangN, ZengW, LiS, YangY (2015) The construction of common and specific significance subnetworks of Alzheimer’s disease from multiple brain regions. Biomed Res Int2015, 394260.
49.
SongJH, YuJT, TanL (2015) Brain-derived neurotrophic factor in Alzheimer’s disease: Risk, mechanisms, and therapy. Mol Neurobiol52, 1477–1493.
50.
NumakawaT, OdakaH, AdachiN (2018) Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci19, 3650.
51.
RantamakiT, KemppainenS, AutioH, StavenS, KoivistoH, KojimaM, AntilaH, MiettinenPO, KarkkainenE, KarpovaN, VesaL, LindemannL, HoenerMC, TanilaH, CastrenE (2013) The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer’s disease. PLoS One8, e68722.
52.
RamserEM, GanKJ, DeckerH, FanEY, SuzukiMM, FerreiraST, SilvermanMA (2013) Amyloid-beta oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell24, 2494–2505.
53.
ZhengZ, SabirzhanovB, KeiferJ (2010) Oligomeric amyloid-beta inhibits the proteolytic conversion of brain-derived neurotrophic factor (BDNF), AMPA receptor trafficking, and classical conditioning. J Biol Chem285, 34708–34717.
54.
BurbachGJ, HellwegR, HaasCA, Del TurcoD, DeickeU, AbramowskiD, JuckerM, StaufenbielM, DellerT (2004) Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci24, 2421–2430.
55.
SchwabC, KlegerisA, McGeerPL (2010) Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta1802, 889–902.
56.
ZhuangB, MancarciBO, TokerL, PavlidisP (2019) Mega-analysis of gene expression in mouse models of Alzheimer’s disease. eNeuro 6, ENEURO.0226-19.2019.
57.
Loera-ValenciaR, GoikoleaJ, Parrado-FernandezC, Merino-SerraisP, MaioliS (2019) Alterations in cholesterol metabolism as a risk factor for developing Alzheimer’s disease: Potential novel targets for treatment. J Steroid Biochem Mol Biol190, 104–114.
58.
Ju HwangC, ChoiDY, ParkMH, HongJT (2019) NF-kappaB as a key mediator of brain inflammation in Alzheimer’s disease. CNS Neurol Disord Drug Targets18, 3–10.
59.
MattsonMP, ChengB, CulwellAR, EschFS, LieberburgI, RydelRE (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron10, 243–254.
60.
NeillT, SchaeferL, IozzoRV (2012) Decorin: A guardian from the matrix. Am J Pathol181, 380–387.
61.
VuTT, MarquezJ, LeLT, NguyenATT, KimHK, HanJ (2018) The role of decorin in cardiovascular diseases: More than just a decoration. Free Radic Res52, 1210–1219.
62.
BocheD, CunninghamC, DocagneF, ScottH, PerryVH (2006) TGFbeta1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis22, 638–650.
63.
OzayR, TurkogluE, GurerB, DolgunH, EvirgenO, ErguderBI, HayirliN, GursesL, SekerciZ, YilmazER (2017) Does decorin protect neuronal tissue via its antioxidant and antiinflammatory activity from traumatic brain injury? An experimental study. World Neurosurg97, 407–415.
64.
CorriganF, ThorntonE, RoismanLC, LeonardAV, VinkR, BlumbergsPC, van den HeuvelC, CappaiR (2014) The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96-110. J Neurochem128, 196–204.
HamiltonA, HolscherC (2012) The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer’s disease. Brain Res1449, 83–93.
69.
BernsteinHG, KeilhoffG, DobrowolnyH, LendeckelU, SteinerJ (2020) From putative brain tumor marker to high cognitive abilities: Emerging roles of a disintegrin and metalloprotease (ADAM) 12 in the brain. J Chem Neuroanat109, 101846.
70.
ZabanehD, KrapohlE, GasparHA, CurtisC, LeeSH, PatelH, NewhouseS, WuHM, SimpsonMA, PutallazM, LubinskiD, PlominR, BreenG (2018) A genome-wide association study for extremely high intelligence. Mol Psychiatry23, 1226–1232.
71.
SagareAP, DeaneR, ZetterbergH, WallinA, BlennowK, ZlokovicBV (2011) Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer’s disease. J Alzheimers Dis24, 25–34.
72.
ZhaoY, ZengCY, LiXH, YangTT, KuangX, DuJR (2020) Klotho overexpression improves amyloid-beta clearance and cognition in the APP/PS1 mouse model of Alzheimer’s disease. Aging Cell19, e13239.
73.
WalkiewiczK, Nowakowska-ZajdelE, KozielP, Muc-WierzgonM (2018) The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer. Cent Eur J Immunol43, 109–113.
74.
MellottTJ, PenderSM, BurkeRM, LangleyEA, BlusztajnJK (2014) IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer’s disease model mice. PLoS One9, e94287.
75.
SteinTD, AndersNJ, DeCarliC, ChanSL, MattsonMP, JohnsonJA (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis. J Neurosci24, 7707–7717.
76.
YuXW, PandeyK, KatzmanAC, AlberiniCM (2020) A role for CIM6P/IGF2 receptor in memory consolidation and enhancement. Elife9, e54781.
LattaCH, SudduthTL, WeekmanEM, BrothersHM, AbnerEL, PopaGJ, MendenhallMD, Gonzalez-OregonF, BraunK, WilcockDM (2015) Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-beta using BV2 microglial cells and APP/PS1 transgenic mice. J Neuroinflammation12, 41.
OyagiA, HaraH (2012) Essential roles of heparin-binding epidermal growth factor-like growth factor in the brain. CNS Neurosci Ther18, 803–810.
87.
OyagiA, MoriguchiS, NittaA, MurataK, OidaY, TsurumaK, ShimazawaM, FukunagaK, HaraH (2011) Heparin-binding EGF-like growth factor is required for synaptic plasticity and memory formation. Brain Res1419, 97–104.
88.
LeandroGS, EvangelistaAF, LoboRR, XavierDJ, MorigutiJC, Sakamoto-HojoET (2018) Changes in expression profiles revealed by transcriptomic analysis in peripheral blood mononuclear cells of Alzheimer’s disease patients. J Alzheimers Dis66, 1483–1495.
89.
MaffiolettiE, TarditoD, GennarelliM, Bocchio-ChiavettoL (2014) Micro spies from the brain to the periphery: New clues from studies on microRNAs in neuropsychiatric disorders. Front Cell Neurosci8, 75.
90.
HuW, CollerJ (2012) What comes first: Translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res22, 1322–1324.
MillanMJ (2017) Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer’s disease: An integrative review. Prog Neurobiol156, 1–68.
97.
CroceN, GelfoF, CiottiMT, FedericiG, CaltagironeC, BernardiniS, AngelucciF (2013) NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: A possible role in neuroprotection?Mol Cell Biochem376, 189–195.
98.
MelliosN, HuangHS, GrigorenkoA, RogaevE, AkbarianS (2008) A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet17, 3030–3042.
99.
SongY, HuM, ZhangJ, TengZQ, ChenC (2019) A novel mechanism of synaptic and cognitive impairments mediated via microRNA-30b in Alzheimer’s disease. EBioMedicine39, 409–421.
100.
CatanaCS, CrisanCA, OpreD, Berindan-NeagoeI (2020) Diagnostic and prognostic value of microRNAs for Alzheimer’s disease: A comprehensive meta-analysis. Med Pharm Rep93, 53–61.
101.
JiangJ, LeeEJ, GusevY, SchmittgenTD (2005) Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res33, 5394–5403.
102.
GanL, DeneckeB (2013) Profiling pre-MicroRNA and mature microRNA expressions using a single microarray and avoiding separate sample preparation. Microarrays (Basel)2, 24–33.
103.
Calvo-Flores GuzmanB, VinnakotaC, GovindpaniK, WaldvogelHJ, FaullRLM, KwakowskyA (2018) The GABAergic system as a therapeutic target for Alzheimer’s disease. J Neurochem146, 649–669.
104.
RiceHC, de MalmazetD, SchreursA, FrereS, Van MolleI, VolkovAN, CreemersE, VertkinI, NysJ, RanaivosonFM, ComolettiD, SavasJN, RemautH, BalschunD, WierdaKD, SlutskyI, FarrowK, De StrooperB, de WitJ (2019) Secreted amyloid-beta precursor protein functions as a GABABR1a ligand to modulate synaptic transmission. Science363, eaao4827.
105.
LiG, LvJ, WangJ, WanP, LiY, JiangH, JinQ (2016) GABAB receptors in the hippocampal dentate gyrus are involved in spatial learning and memory impairment in a rat model of vascular dementia. Brain Res Bull124, 190–197.
RiceRA, BerchtoldNC, CotmanCW, GreenKN (2014) Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production. Neurobiol Aging35, 1002–1011.
110.
LiuS, WangY, WorleyPF, MattsonMP, GaianoN (2015) The canonical Notch pathway effector RBP-J regulates neuronal plasticity and expression of GABA transporters in hippocampal networks. Hippocampus25, 670–678.
111.
KickingerS, HellsbergE, FrolundB, SchousboeA, EckerGF, WellendorphP (2019) Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function. Neuropharmacology161, 107644.
KnightLS, PiibeQ, LambieI, PerkinsC, YanceyPH (2017) Betaine in the brain: Characterization of betaine uptake, its influence on other osmolytes and its potential role in neuroprotection from osmotic stress. Neurochem Res42, 3490–3503.
NieC, NieH, ZhaoY, WuJ, ZhangX (2016) Betaine reverses the memory impairments in a chronic cerebral hypoperfusion rat model. Neurosci Lett615, 9–14.
116.
ShiH, WangXL, QuanHF, YanL, PeiXY, WangR, PengXD (2019) Effects of betaine on LPS-stimulated activation of microglial M1/M2 phenotypes by suppressing TLR4/NF-kappaB pathways in N9 cells. Molecules24, 367.
117.
AmiraslaniB, SabouniF, AbbasiS, NazemH, SabetM (2012) Recognition of betaine as an inhibitor of lipopolysaccharide-induced nitric oxide production in activated microglial cells. Iran Biomed J16, 84–89.
118.
HuaX, SuZ, DengR, LinJ, LiDQ, PflugfelderSC (2015) Effects of L-carnitine, erythritol and betaine on pro-inflammatory markers in primary human corneal epithelial cells exposed to hyperosmotic stress. Curr Eye Res40, 657–667.
119.
GoEK, JungKJ, KimJY, YuBP, ChungHY (2005) Betaine suppresses proinflammatory signaling during aging: The involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. J Gerontol A Biol Sci Med Sci60, 1252–1264.
